New drug combo shows promise against rare skin cancer
NCT ID NCT04869137
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 26 times
Summary
This study tested a combination of two drugs, lenvatinib and pembrolizumab, given before surgery to people with Merkel cell carcinoma, a rare and aggressive skin cancer. The goal was to see if the drugs could shrink or eliminate the tumor before it was removed. The trial enrolled 26 adults with stage II, III, or IV cancer. The main measure of success was whether no cancer cells remained in the removed tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MERKEL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.